CIK 0001635088
- Large accelerated filer
Roivant Sciences Ltd.
Sign in to watch- Ticker
- ROIV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Mar 31
- Incorporated
- Bermuda
- Entity type
- Operating
- EIN
- 981173944
- Phone
- +44 12955950
- Business address
- 7TH FLOOR, 50 BROADWAY, LONDON, United Kingdom, SW1H 0DB
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $70,369,463
- in 12 filings, $45.5M under 10b5-1 plans
Net −$70,369,463. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-12 | Gline Matthew CEO | Other disposition | −41,179 | $40.36 | $1.7M | 16,400,638 |
| 2026-11-12 | Gline Matthew CEO | Other disposition | −7,809 | $41.13 | $321K | 16,392,829 |
| 2026-11-12 | Gline Matthew CEO | Shares withheld for taxes | −1,600 | $41.85 | $67K | 16,391,229 |
| 2026-11-11 | Gline Matthew CEO | Other disposition | −30,083 | $41.63 | $1.3M | 16,460,722 |
| 2026-11-11 | Gline Matthew CEO | Other disposition | −18,905 | $42.01 | $794K | 16,441,817 |
| 2026-11-10 | Gline Matthew CEO | Other disposition | −25,841 | $40.43 | $1.0M | 16,523,295 |
| 2026-11-10 | Gline Matthew CEO | Other disposition | −32,490 | $41.13 | $1.3M | 16,490,805 |
| 2026-10-16 | Gline Matthew CEO | Shares withheld for taxes | −34,638 | $33.53 | $1.2M | 16,549,136 |
| 2026-09-30 | Gline Matthew CEO | Shares withheld for taxes | −76,171 | $36.57 | $2.8M | 16,583,774 |
| 2026-06-30 | Gline Matthew CEO | Shares withheld for taxes | −76,171 | $35.39 | $2.7M | 16,659,945 |
| 2026-04-16 | Gline Matthew CEO | Sale | −289,774 | $29.16 | $8.4M | 16,736,116 |
| 2026-03-31 | Gline Matthew CEO | Shares withheld for taxes | −304,684 | $27.70 | $8.4M | 17,025,890 |
| 2026-03-30 | Gline Matthew CEO | Option exercise | +97,319 | 17,384,400 | ||
| 2026-03-30 | Gline Matthew CEO | Shares withheld for taxes | −53,826 | $26.41 | $1.4M | 17,330,574 |
| 2026-03-30 | Gline Matthew CEO | Option exercise · Capped Value Appreciation Rights | −2,178,150 | $11.50 | $25.0M | 0 |
| 2025-12-15 | Gline Matthew CEO | Option exercise | +234,096 | $4.06 | $950K | 17,521,177 |
| 2025-12-15 | Gline Matthew CEO | Sale | −230,357 | $21.68 | $5.0M | 17,290,820 |
| 2025-12-15 | Gline Matthew CEO | Other disposition | −3,739 | $21.68 | $81K | 17,287,081 |
| 2025-12-15 | Gline Matthew CEO | Option exercise | +1,363,711 | $12.68 | $17.3M | 18,650,792 |
| 2025-12-15 | Gline Matthew CEO | Sale | −566,116 | $21.68 | $12.3M | 18,084,676 |
Page 1 of 4 · 66 trades